title: No significant effect of orally administered chemokine receptor 1 antagonist on intercellular adhesion molecule-3 expression in relapsing--remitting multiple sclerosis patients.
abstract: We investigated the expression of intercellular adhesion molecules ICAM-1 and ICAM-3 on peripheral blood mononuclear cells in a subgroup of 34 patients with relapsing-remitting multiple sclerosis who were treated orally with the chemokine receptor 1 antagonist BX 471 in a 16-week, randomised, double-blind, placebo-controlled phase II study. ICAM-1 and ICAM-3 expression was measured by flow cytometry at different time points during and after therapy and compared using multivariate analysis of variance and non-parametric Mann Whitney test. ICAM-3 expression on CD14( +) peripheral blood mononuclear cells was increased in the verum group under therapy, but did not differ significantly between the verum and placebo groups. Most likely, this trend represents a small epiphenomenon only mediated by receptor cross-talk and feedback mechanisms.
authors.affiliation: Department of Neurology, Justus Liebig University, Giebetaen Germany. reinhard.reuss@neuro.med.uni-giessen.de
authors.forename: R
authors.initials: R
authors.lastname: Reuss
authors.forename: V
authors.initials: V
authors.lastname: Schreiber
authors.forename: A
authors.initials: A
authors.lastname: Klein
authors.forename: C
authors.initials: C
authors.lastname: Infante-Duarte
authors.forename: M
authors.initials: M
authors.lastname: Filippi
authors.forename: W
authors.initials: W
authors.lastname: Pabst
authors.forename: C
authors.initials: C
authors.lastname: Pohl
authors.forename: P
authors.initials: P
authors.lastname: Oschmann
mesh_terms: D000284:Administration, Oral; D015703:Antigens, CD / Q000097:blood*; D015815:Cell Adhesion Molecules / Q000097:blood*; D004311:Double-Blind Method; D005434:Flow Cytometry; D005858:Germany; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage*; D018799:Intercellular Adhesion Molecule-1 / Q000097:blood; D007558:Italy; D007963:Leukocytes, Mononuclear / Q000187:drug effects* / Q000276:immunology; D018950:Lipopolysaccharide Receptors / Q000097:blood; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy* / Q000276:immunology; D010671:Phenylurea Compounds / Q000008:administration & dosage*; D010880:Piperidines / Q000008:administration & dosage*; D054389:Receptors, CCR1 / Q000037:antagonists & inhibitors*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D015703:Antigens, CD; C515300:CCR1 protein, human; D015815:Cell Adhesion Molecules; C483616:ICAM3 protein, human; D007155:Immunologic Factors; D018950:Lipopolysaccharide Receptors; D010671:Phenylurea Compounds; D010880:Piperidines; D054389:Receptors, CCR1; D018799:Intercellular Adhesion Molecule-1; C411885:BX 471